Nebius Group Surges to 74th in Daily Rankings with 8.76 Billion in Trading Volume

On June 24, 2025, Nebius Group (NBIS) saw a significant surge in trading volume, reaching 8.76 billion, marking a 53.43% increase from the previous day. This substantial rise placed Nebius at the 74th position in the daily stock market rankings, with its stock price increasing by 7.46%.

Nebius, a full-stack AI infrastructure provider, has announced the winners of its inaugural AI Discovery Awards. The awards, which total over $850,000 in GPU credits, support pioneering companies in biotech, drug discovery, genomics, multiomics, and healthcare diagnostics. The winners were selected from 257 global applications by a panel of 19 independent judges from leading biotech, pharma, research, and venture capital organizations.

The winners represent validated AI solutions with clear paths to market impact. Ataraxis AI, in the biotechnology category, developed a cancer treatment prediction platform that achieved 30% higher accuracy than standard genomic tests. Aikium, in drug discovery, targets "undruggable" proteins using its Yotta-ML² platform. Transcripta Bio, in genomics and multiomics, built a high-resolution transcriptomic atlas to power AI models predicting biological responses from drug molecules. MetaSight Diagnostics, in health tech, pioneers population-scale disease diagnostics through advanced blood testing.

Nebius's AI Discovery Awards aim to connect promising companies leveraging AI in healthcare and life sciences with the computational infrastructure and expertise needed to scale their innovations. The awards provide significant financial support, mentorship, and networking opportunities to the winners. This initiative underscores Nebius's commitment to accelerating AI innovation in healthcare and life sciences, positioning the company as a leader in the AI infrastructure space.